US EditionAstellas Adds to Claudin Clout with $1.3bn+ Evopoint Deal
- On May 29, 2025, Astellas Pharma and Evopoint Biosciences announced a deal granting Astellas exclusive rights to develop and market the investigational drug XNW27011 outside of Greater China, with the agreement originating from Tokyo and Suzhou.
- Astellas secured the deal to expand its oncology pipeline with XNW27011, a clinical-stage ADC targeting CLDN18.2, currently in Phase 1/2 trials in China.
- XNW27011 features a unique antibody-drug conjugate design that incorporates a topoisomerase I inhibitor linked via specialized chemistry, a strategy proven effective in previously approved cancer treatments, and has shown encouraging results as a standalone therapy.
- Evopoint will obtain an initial payment of $130 million upfront, with the potential to earn up to $1.34 billion in additional milestone payments and royalties contingent upon XNW27011’s regulatory approval and achievement of sales milestones.
- This agreement supports Astellas' precision oncology leadership and specialization in CLDN18.2-targeted therapies to address unmet needs in gastric and pancreatic cancers.
Insights by Ground AI
Does this summary seem wrong?
56 Articles
56 Articles
All
Left
8
Center
14
Right
2
Rutland Herald+50 Reposted by 50other sources
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011
Clinical Trials ArenaReposted by 
pharmaceutical-technology.com
pharmaceutical-technology.comAstellas and Evopoint sign ADC licensing deal
Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a CLDN18.2-targeting clinical-stage ADC.The post Astellas and Evopoint sign ADC licensing deal appeared first on Clinical Trials Arena.
Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences
Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a Claudin18.2-targeted antibody-drug conjugate from Evopoint Biosciences. The Suzhou-based biotech could receive another $70 million ...
Coverage Details
Total News Sources56
Leaning Left8Leaning Right2Center14Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 33%
C 58%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
